DISCOVERY CENTERS

Looking for the next big breakthroughs in dementia and cancer research? Here are the top 3 places to watch — powered by Eisai.


EISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY (G2D2)

EISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY (G2D2)

G2D2 is on a mission to accelerate the discovery of breakthrough therapeutics for dementia patients and their families. How? By harnessing the combined power of human genetics, data sciences and precision chemistry.

open quote

ADVANCES IN HUMAN BIOLOGY AND PRECISION CHEMISTRY HAVE GIVEN US AN UNPRECEDENTED SCIENTIFIC ARSENAL IN THE FIGHT TO ERADICATE ALZHEIMER’S DISEASE.

close quote

Nadeem Sarwar
President, G2D2

H3 BIOMEDICINE (H3)

H3 BIOMEDICINE (H3)

One big factor in determining how cancer occurs and spreads in your body is your genome — your complete set of DNA. Now, what if there were drugs tailored just for people who share your genomic makeup? Drugs that could precisely target the way cancer affects you?

That’s the quest that drives H3 researchers. They’re rapidly developing an array of powerful therapies that are optimized for cancer patients based on their genomic makeup.

$200M

H3 BIOMEDICINE WAS LAUNCHED IN 2011 WITH A $200 MILLION COMMITMENT FROM EISAI PLUS ADDITIONAL FUNDING FOR CLINICAL PROGRAMS.

 
EPOCHAL PRECISION ANTI-CANCER THERAPEUTICS (EPAT)

EPOCHAL PRECISION ANTI-CANCER THERAPEUTICS (EPAT)

Chemotherapy is indiscriminate: it kills healthy as well as sick cells. But what if you could create a therapy that exclusively targets cancer cells — and kills them with precisely the right chemical guided by cancer-targeting biological antibodies? That's the kind of precision medicine and diagnostics we're working on at EPAT. We're developing oncology drugs that utilize our unique Antibody-Drug Conjugate (ADC) technology, bispecifics and other emerging biologics. Ultimately, we aim to deliver better therapeutic results with fewer side effects.

EISAI'S INVESTMENTS IN THESE CENTERS IS OUR MOONSHOT

The stakes are sky-high. The scientific challenges: mind-boggling. And there are no guarantees of success. So — in an era of R&D cutbacks — why on earth is Eisai charging ahead? Why such urgency?

Just ask people living with cancer and dementia.

For them, this is literally life-and-death.

With these people first in our thoughts, there is no hesitation. We will never stop pursuing the next breakthrough that can improve their lives.

For us at Eisai, the questions all come down to this: If not us, who? If not now, when?